Curriculum Vitae of Jun Lu

Affiliation: Prof. Jun Lu, PhD,

College of Pharmaceutical Sciences,

Southwest University,

No.2 Tiansheng Road, Beibei District,

Chongqing 400715, China.

Email: junlu@swu.edu.cn

Current Research Interests:

Study on the mechanism and development of the drugs based on targeting the regulation of thiol redox system, and the novel biopharmaceutical technology.  

Member of Editorial Board

Frontier in Physiology

BioMed Research International

Current Pharmaceutical Biotechnology

Education

1988.09-1992.07   B. Sc. in Chemistry, Sichuan University, ChengDu, P. R. China

1992.09-1995.07   M. Sc. in Bioinorganic Chemistry, Sichuan University, ChengDu, P. R.

China

1995.09-1998.12   Ph. D. in Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, P. R. China

Working experience

2018.03-         Director of the Teaching and Research in Pharmacology Section, College of Pharmaceutical Sciences, Southwest University, China

2016.06-         Professor, College of Pharmaceutical Sciences, Southwest University, China

2013.07-2016.05  Senior Researcher (Senior Lab Manager), Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden

2009.04-2013.03  Assistant Professor (Forskarassistent), Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden

2005.09-2009.03   Researcher, Medical Nobel Institute for Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden

2003.09-2005.08   Postdoctoral fellow, Medical Nobel Institute for Biochemistry, Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

2000.11-2002.11  STA fellow, JSPS fellow, The Institute of Physical and Chemical Research (RIKEN), Saitama, Japan

1999.01-2000.11   Assistant Professor, head of research group, Key Laboratory of Rare Earth Chemistry and Physics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, P. R. China

Publications (*corresponding authors)

1. Zhao Y, Zuo X, Liu S, Qian W, Tang X, Lu J*. A Fluorescent Probe to Detect Quick Disulfide Reductase Activity in Bacteria. Antioxidants (Basel). 2022, 11(2):377.

2. Zuo X, Zhao Y, Zhao J, Ouyang Y, Qian W, Hou Y, Yu C, Ren X, Zou L, Fang J, Lu J*. A fluorescent probe for specifically measuring the overall thioredoxin and glutaredoxin reducing activity in bacterial cells. Analyst. 2022, 147(5):834-840.

3. Li J, Cheng P, Li S, Zhao P, Han B, Ren X, Zhong JL, Lloyd MD, Pourzand C, Holmgren A, Lu J*. Selenium Status in Diet Affects Acetaminophen-Induced Hepatotoxicity via Interruption of Redox Environment. Antioxid Redox Signal. 2021, 34(17):1355-1367.

4. Cheng P, Liu H, Li Y, Pi P, Jiang Y, Zang S, Li X, Fu A, Ren X, Xu J, Holmgren A, Lu J*. Inhibition of Thioredoxin Reductase 1 Correlates With Platinum-Based Chemotherapeutic Induced Tissue Injury. Biochem Pharmacol. 2020, 175:113873.

5. Dong C, Zhou J, Wang P, Li T, Zhao Y, Ren X, Lu J, Wang J, Holmgren A, Zou L. Topical Therapeutic Efficacy of Ebselen Against Multidrug-Resistant Staphylococcus aureus LT-1 Targeting Thioredoxin Reductase. Front Microbiol.2020, 10, 3016.

6. Lu J*. Therapy Based on the Regulation of Thiol-dependent Redox Systems. (Editorial) Curr Med Chem.2020, 27(12):1876-1877.

7. Ouyang Y, Li J, Peng Y, Huang Z, Ren Q, Lu J*. The Role and Mechanism of Thiol-Dependent Antioxidant System in Bacterial Drug Susceptibility and Resistance. Curr Med Chem. 2020, 27(12):1940-1954.

8. Li J, Zuo X, Cheng P, Ren X, Sun S, Xu J, Holmgren A, Lu J*. The production of reactive oxygen species enhanced with the reduction of menadione by active thioredoxin reductase. Metallomics. 2019, 11(9):1490-1497.

9. Chen X, Chen H, Zhang H, Peng Y, Deng F, Gao J, Chai C, Tang S, Zuo X, Lu J, Du H. Characterization of Synergistic Antibacterial Effect of Silver Nanoparticles and Ebselen. Artif Cells Nanomed Biotechnol. 2019, 47 (1), 3338-3349.

10. Ren X, Sengupta R, Lu J, Lundberg J, Holmgren A. Characterization of Mammalian Glutaredoxin Isoforms as S-denitrosylases. FEBS Lett. 2019, 593 (14), 1799-1806.

11. Ren X, Santhosh SM, Coppo L, Ogata FT, Lu J, Holmgren A. The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress. Free Radic Biol Med. 2019, 134:350-358.

12. Zou L, Wang J, Gao Y, Ren X, Rottenberg ME, Lu J*, Holmgren A*. Synergistic antibacterial activity of silver with antibiotics correlating with the upregulation of the ROS production, Sci Rep., 2018, 8: 11131

13. Ouyang Y, Peng Y, Li J, Holmgren A, Lu J*. Modulation of thiol-dependent redox system by metal ions via thioredoxin and glutaredoxin systems. Metallomics. 2018, 10(2):218-228.

14. Haffo L, Lu J, Bykov V, Martin S, Ren X, Coppo L, Wiman K, Holmgren A, Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246, Sci Rep. 2018; 8: 12671

15. Ren X, Zou L, Lu J, Holmgren A. Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic. Free Radic Biol Med. 2018, 127:238-247

16. Ren X, Lu J*, Holmgren A*, Thioredoxin and Cellular Redox Systems: Beyond Protein Disulfide Bond Reduction, in “Chemical Biology No. 9: Oxidative Folding of Proteins: Basic Principles, Cellular Regulation and Engineering”, Edited by Matthias J. Feige, Published by Royal Society of Chemistry, 2018, 355-377. (Book Chapter）

1. Lu J*, Ren X, Zou L, Holmgren A, Ebselen and Thioredoxin Systems in Human Health, Disease and Therapeutic Potential, in "Organoselenium Compounds in Biology and Medicine: Synthesis, Biological and Therapeutic Treatments", Edited by Vimal Kumar Jain and K. Indira Priyadarsini, Published by Royal Society of Chemistry, 2018, 303-316. (Book Chapter）

   Ren X, Zou L, Zhang X, Branco V, Wang J, Carvalho C, Holmgren A, Lu J*. Redox Signaling Mediated by Thioredoxin and Glutathione Systems in the Central Nervous System. Antioxid Redox Signal. 2017, 27(13):989-1010

   Zou L, Lu J*, Wang J, Ren X, Zhang L, Gao Y, Rottenberg ME, Holmgren A*. Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections. EMBO Mol Med. 2017, 9(8):1165-1178.

   Branco V, Coppo L, Solá S, Lu J, Rodrigues CMP, Holmgren A, Carvalho C. Impaired cross-talk between the thioredoxin and glutathione systems is related to ASK-1 mediated apoptosis in neuronal cells exposed to mercury. Redox Biol. 2017, 13:278-287.

   Rodriguez-Garcia A, Hevia D, Mayo JC, Gonzalez-Menendez P, Coppo L, Lu J, Holmgren A, Sainz RM. Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells. Redox Biol. 2017, 12:634-647.

   Álvarez-Zaldiernas C, Lu J*, Zheng Y, Yang H, Blasi J, Solsona C*, Holmgren A*. Cellular Redox Systems Impact the Aggregation of Cu, Zn Superoxide Dismutase Linked to Familial Amyotrophic Lateral Sclerosis. J Biol Chem., 2016, 291(33):17197-17208.

2. Olivera C, Ren X, Vodnala SK, Lu J, Coppo L, Leepiyasakulchai C, Holmgren A, Kristensson K, Rottenberg M, Nitric Oxide Protects against Infection-Induced Neuroinflammation by Preserving the Stability of the Blood-Brain Barrier. PLoS Pathog, 2016, 12(2): e1005442.

3. Rodrigues J, Branco V, Lu J, Holmgren A, Carvalho C, Toxicological effects of thiomersal and ethylmercury: inhibition on thioredoxin system and NADP+-dependent dehydrogenases of the pentose phosphate pathway, Toxicology and Applied Pharmacology, 2015, 286(3): 216-223.

25. Zhang X, Lu J*, Ren X, Du Y, Zheng Y, Ioannou PV, Holmgren A*, Oxidation of structural cysteine residues in thioredoxin 1 by aromatic arsenicals enhances cancer cell cytotoxicity caused by the inhibition of thioredoxin reductase 1. Free Radic Biol Med. 2015, 89:192-200.

1. Shelar SB, Kaminska KK, Reddy SA, Kumar D, Tan CT, Yu VC, Lu J, Holmgren A, Hagen T, Chew EH, Thioredoxin-dependent regulation of AIF-mediated DNA damage, Free Radic Biol Med, 2015, 87: 125-136.

27. Lu J, Holmgren A, The thioredoxin superfamily in oxidative protein folding, Antioxid Redox Signal, 2014, 457-470.

1. Branco V, Godinho-Santos A, Gonçalves J, Lu J, Holmgren A, Carvalho C, Mitochondrial thioredoxin reductase inhibition, selenium status, and Nrf-2 activation are determinant factors modulating the toxicity of mercury compounds, Free Radic Biol Med, 2014, 73: 95-105.

29. Lu J*, Holmgren A*, The thioredoxin antioxidant system. Free Radic Biol Med, 2014, 66: 75-87.

1. Zhang H, Du Y, Zhang X, Lu J, Holmgren A, Glutaredoxin 2 Reduces Both Thioredoxin 2 and Thioredoxin 1 and Protects Cells from Apoptosis Induced by Auranofin and 4-Hydroxynonenal, Antioxid Redox Signal, 2014, 21(5): 669-681.

2. Montano SJ, Lu J, Gustafsson TN, Holmgren A, Activity assays of mammalian thioredoxin and thioredoxin reductase: Fluorescent disulfide substrates, mechanisms, and use with tissue samples, Anal Biochem, 2014, 449: 139-146.

3. Du Y, Zhang H, Zhang X, Lu J, Holmgren A, Thioredoxin 1 is inactivated due to oxidation induced by peroxiredoxin under oxidative stress and reactivated by the glutaredoxin system, J Biol Chem, 2013, 288(45): 32241-32247.

33. Lu J, Vodnala SK, Gustavsson AL, Gustafsson TN, Sjöberg B, Johansson HA, Kumar S, Tjernberg A, Engman L, Rottenberg ME, Holmgren A, Ebsulfur is a benzisothiazolone cytocidal inhibitor targeting the trypanothione reductase of Trypanosoma brucei, J Biol Chem, 2013, 288(38): 27456-27468.

34. Lu J, Vlamis-Gardikas A, Kandasamy K, Zhao R, Gustafsson TN, Engstrand L, Hoffner S, Engman L, Holmgren A, Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione, FASEB J, 2013, 27(4): 1394-1403.

35. Lu J, Holmgren A, Thioredoxin system in cell death progression, Antioxid Redox Signal, 2012, 17(12): 1738-1747.

1. Branco V, Ramos P, Canario J, Lu J, Holmgren A, Carvalho C, Biomarkers of adverse response to mercury: histopathology versus thioredoxin reductase activity, J Biomed Biotechnol, 2012, 359879.

2. Du Y, Zhang H, Lu J, Holmgren A. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose, J Biol Chem, 2012, 287(45): 38210-38219.

3. Gustafsson TN, Sahlin M, Lu J, Sjoberg BM, Holmgren A, Bacillus anthracis thioredoxin systems - characterization and role as electron donors for ribonucleotide reductase, J Biol Chem, 2012, 287(47): 39686-39697.

4. Paz MM, Zhang X, Lu J, Holmgren A, A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase, Chem Res Toxicol, 2012, 25(7): 1502-1511.

5. Lu J, Holmgren A. Selenoprotein and the thioredoxin system, Chapter 12 in Selenium: Its molecular biology and role in human health. Springer Verlag, New York. Edited by Hatfield D. L., Berry, M. J. and Gladyshev, V. N., 2012, 153-165. (Book Chapter)

6. Branco V, Canário J, Lu J, Holmgren A, Carvalho C, Mercury and selenium interaction in vivo: effects on thioredoxin reductase and glutathione peroxidase. Free Radic Biol Med, 2012, 52(4): 781-793.

7. Carvalho CM, Lu J, Zhang X, Arnér ES, Holmgren A, Effects of selenite and chelating agents on mammalian thioredoxin reductase inhibited by mercury: implications for treatment of mercury poisoning, FASEB J, 2011, 25(1): 370-381.

43. Zhang X, Zheng YJ, Fried LE, Du Y, Montano SJ, Sohn A, Lefkove B, Holmgren L, Arbiser JL, Holmgren A*, Lu J*, Disruption of mitochondrial thioredoxin system as a cell death mechanism of cationic triphenylmethanes, Free Radic Biol Med, 2011, 50(7): 811-20.

1. Papp LV, Lu J, Bolderson E, Boucher D, Singh R, Holmgren A, Khanna KK, SECIS-Binding Protein 2 Promotes Cell Survival by Protecting Against Oxidative Stress, Antioxid Redox Signal, 2010, 12(7): 797-808.

2. Schoenmakers E, Agostini M, Mitchell C, Schoenmakers N, Papp L, Rajanayagam O, Padidela R, Ceron-Gutierrez L, Doffinger R, Prevosto C, Luan J, Montano S, Lu J, Castanet M, Clemons N, Groeneveld M, Castets P, Karbaschi M, Aitken S, Dixon A, Williams J, Campi I, Blount M, Burton H, Muntoni F, O'Donovan D, Dean A, Warren A, Brierley C, Baguley D, Guicheney P, Fitzgerald R, Coles A, Gaston H, Todd P, Holmgren A, Khanna KK, Cooke M, Semple R, Halsall D, Wareham N, Schwabe J, Grasso L, Beck-Peccoz P, Ogunko A, Dattani M, Gurnell M, Chatterjee K. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans, J Clin Invest, 2010, 120(12): 4220-4235.

3. Holmgren A, Lu J, Thioredoxin and thioredoxin reductase: Current research with special reference to human disease, BBRC, 2010, 396(1): 120-124.

4. Lu J, Holmgren A, Glutaredoxin catalysis and function in redox regulation, in "Handbook of the methods for studying redox signaling ", Publisher: Mary Ann Liebert, New York, Editor: Dipak K Das, 2010, 3-6. (Book Chapter）

48. Lu J*, Zhong L, Lönn ME, Burk RF, Hill KE, Holmgren A*, Penultimate selenocysteine residue replaced by cysteine in thioredoxin reductase from selenium-deficient rat liver, FASEB J, 2009, 23(8): 2394-2402.

49. Lu J, Holmgren A, Selenoproteins. J Biol Chem, 2009, 284(2): 723-727.

50. Lu J, Berndt C, Holmgren A, Metabolism of selenium compounds catalyzed by the mammalian selenoprotein thioredoxin reductase. Biochim Biophys Acta, 2009, 1790(11): 1513-1519.

51. Gurmu D, Lu J, Johnson KA, Nordlund P, Holmgren A, Erlandsen H, The crystal structure of the protein YhaK from Escherichia coli reveals a new subclass of redox sensitive enterobacterial bicupins, Proteins, 2009, 74(1): 18-31.

1. Fridlich R, Delalande F, Jaillard C, Lu J, Poidevin L, Cronin T, Perrocheau L, Millet-Puel G, Niepon ML, Poch O, Holmgren A, Van Dorsselaer A, Sahel JA, Léveillard T, The thioredoxin-like protein RdCVFL interacts with Tau and inhibits its phosphorylation in the retina, Mol Cell Proteomics, 2009, 8(6): 1206-1218.

2. Chew EH, Lu J, Bradshaw TD, Holmgren A, Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity, FASEB J, 2008, 22(6): 2072-83.

3. Carvalho CM, Chew EH, Hashemy SI, Lu J, Holmgren A, Inhibition of human thioredoxin system: A molecular mechanism of mercury toxicity, J Biol Chem, 2008, 283(18): 11913-11923.

55. Lu J, Chew EH, Holmgren A, Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide, Proc Natl Acad Sci U S A, 2007, 104(30): 12288-12293.

1. Papp LV, Lu J, Holmgren A, Khanna KK, From selenium to selenoproteins: Synthesis, identity and their role in human health, Antioxid. Redox Signal, 2007, 9(7): 775-806.

2. Gustafsson TN, Sandalova T, Lu J, Holmgren A, Schneider G, High-resolution structures of oxidized and reduced thioredoxin reductase from Helicobacter pylori, Acta Crystallogr D Biol Crystallogr, 2007, 63(Pt 7): 833-843.

3. Papp LV, Lu J, Striebel F, Kennedy D, Holmgren A, Khanna KK, The Redox State of SECIS Binding Protein 2 Controls Its Localization and Selenocysteine Incorporation Function, Mol Cell Biol, 2006, 26: 4895-4910.

4. Lu J, Papp LV, Fang J, Rodriguez-Neto S, Zhivotovsky B, Holmgren A, Inhibition of mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quercetin anticancer activity, Cancer Res, 2006, 66(8): 4410-4418.

5. Fang J, Lu J, Holmgren A, Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity, J Biol Chem, 2005, 280(26): 25284-25290.

6. Zheng YJ, Lu J, Liu LY, Zhao DQ, Ni JZ. Fluorescence analysis of aldolase dissociation from the N-terminal of the cytoplasmic domain of band 3 induced by lanthanide. BBRC. 2003, 303(2): 433-439.

62. Lu J*, Zheng Y, Yamagishi H, Odaka M*, Tsujimura M, Maeda M, Endo I, Motif CXCC in nitrile hydratase activator is critical for NHase biogenesis in vivo, FEBS Lett, 2003, 553(3): 391-396.

SCI citation number: >6000, H-index: 33.

Patent：

1. Holmgren A, Lu J, Zou LL, Antibiotic compositions comprising silver and selenium. International publication (PCT) No.: WO 2018/104777 A1， Patent open date：2018.6.14

2. Holmgren A, Lu J, Vlamis-Gardikas A, Zhao R, Kandasamy K, Engman L, Engstrand L, Hoffner S. Bacterial thioredoxin reductase inhibitions and methods for use thereof. U.S. Patent, patent No.: US 2014/0088149 A1. Patent open date：2014.3.27.

   Positions for Master graduate students and postdoctoral researchers are available!